by Tony Akiwumi | Oct 29, 2025 | Pharma / Market Access
A decade ago, rare disease development was seen as niche science with limited commercial logic. Today, it sits at the heart of biopharma innovation. Over half of all new drugs approved in recent years target rare or ultra-rare conditions, and large companies are...
by Tony Akiwumi | Oct 28, 2025 | Pharma / Market Access
When I first worked with a small biotech team preparing to launch its first therapy, the energy in the room was electric. The science was extraordinary, the leadership hungry, and the investors impatient. Yet, amid the whiteboard diagrams of trial designs and...
by Tony Akiwumi | Sep 27, 2025 | Pharma / Market Access
I’ve always loved designing early stage assets for success, supporting teams to shape the future of innovative therapies. Differentiating early-stage assets—those in Phase 1 and Phase 2 signal-seeking development—requires a strategic blend of clinical,...
by Tony Akiwumi | Sep 27, 2025 | Pharma / Market Access
The Same Molecule, Two Different Fates Depending On Who You Give It To! Warning: This article contains a bold recommendation on how to proactively develop drugs that payers, HCPs, and patients want. A dear friend and muse often makes a deceptively simple but deeply...
by Tony Akiwumi | Sep 26, 2025 | Pharma / Market Access
For years, “market access” has been the holy grail of every pharma launch—a checklist of regulatory approvals, pricing negotiations, and payer agreements. It’s the moment when companies declare, “We’ve arrived.” But here’s the truth no one says out loud: Market access...
by Tony Akiwumi | Sep 26, 2025 | Pharma / Market Access
Introduction: The Innovation Paradox Pharma has never been more scientifically capable. Gene therapies are rewriting what we thought possible. AI is reshaping discovery and development. Precision medicine is turning blanket treatments into targeted solutions. And...
